보고서 요약(국문)

개요
전 세계 진균성 각막염 치료 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
진균성 각막염은 각막의 진균 감염으로, 실명을 유발할 수 있습니다. 일반적으로 눈의 충혈, 통증, 시야 흐림 등의 증상이 나타납니다. 이는 안구 표면을 침범할 수 있는 다양한 병원성 진균에 의해 발생하는 각막 감염입니다.
진균성 각막염은 대개 서서히 진행되는 질환으로, 특히 대부분의 미생물성 각막 감염을 차지하는 세균성 각막 질환과 같이 유사한 증상을 보이는 다른 유형의 각막 질환과 구별해야 합니다. 진균성 각막염을 유발하는 가장 흔한 아스페르길루스 종은 A. flavus와 A. fumigatus입니다.

시장 동향
증가하는 진균성 각막염 부담
진균성 각막염의 증가 추세는 시장 성장의 중요한 동인입니다. 진균성 각막염은 특히 야외 작업자에게 흔한 안구 감염입니다. 대부분의 경우, 눈 외상, 코르티코스테로이드 사용 또는 콘택트렌즈 착용이 유발 요인입니다. 진균성 각막염 치료에는 일반적으로 국소 약물이 사용되며, 드물게 수술이 필요할 수 있습니다.
예를 들어, 미국에서는 플로리다와 같은 남부의 따뜻한 지역이 북부의 서늘한 지역보다 진균성 각막염 발생률이 더 높습니다. 미국에서 진균 감염을 일으키는 가장 흔한 분리균은 푸사리움(Fusarium), 칸디다(Candida) 및 아스페르길루스(Aspergillus)입니다.
또한, 미국 국립보건원(NIH)의 2022년 보고서에 따르면, 젊은 남성 성인의 진균성 각막염 발생률이 더 높았는데, 이는 야외 활동 증가 및 외상 이력과 관련이 있을 수 있습니다. 이 주요 연구에서 중국인 진균성 각막염 환자의 60% 이상이 남성이었고, 75% 이상이 30~60세 연령대였습니다.
또한 미국 안과학회에 따르면 진균성 각막염의 유병률은 지역별로 다르며 남인도에서 가장 높지만(각막 궤양의 36.7%), 서인도(36.3%)와 동인도(26.4%)에서도 흔합니다. 북인도에서는 진균성 각막염이 각막 궤양의 원인으로 훨씬 드뭅니다(7.3%).
더욱이 진균성 각막염에 대한 인식 증가와 치료제 임상 시험 증가와 같은 주요 성장 동력이 향후 시장 성장을 견인할 것으로 예상됩니다.
치료제 관련 부작용
암포테리신 B와 같은 치료제는 인체 세포막의 콜레스테롤과 상호작용하여 독성을 나타낼 수 있습니다. 암포테리신 B의 가장 흔한 부작용으로는 칼륨 손실, 마그네슘 손실, 신독성, 발열, 아나필락시스 등이 있습니다. 따라서 이러한 요인들이 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 진균성 각막염 시장은 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 치료가 시장 점유율의 약 56.7%를 차지했습니다.
진균성 각막염은 처방 항진균제를 수개월 동안 복용하여 치료할 수 있습니다. 나타마이신은 현재 푸사리움과 아스페르길루스에 가장 효과적인 약물로 여겨집니다. 새로운 임상 시험 증가와 치료제 개발 연구 개발로 인해 약물 치료는 향후 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다.
예를 들어, clinicaltrials.com에 따르면 2021년 11월 5일 샌프란시스코 캘리포니아 대학교는 가시아메바 각막염 및 진균성 각막염 감염 감소를 위해 녹색광을 이용한 로즈 벵갈 전자기 활성화에 대한 임상 시험을 진행했습니다. 현재 3상 임상시험이 진행 중이며, 연구 완료 예정일은 2025년 7월입니다.
또한, 인도 L.V. 프라사드 안과 연구소에서는 무작위 이중맹검 임상시험을 통해 진균성 각막염에 대한 1% 보리코나졸과 5% 나타마이신 병용치료의 2/3상 임상시험을 완료했습니다.
지역 분석
북미는 전 세계 진균성 각막염 치료 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
전 세계 진균성 각막염 치료 시장은 북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카로 구분됩니다.
북미는 진균성 각막염 발병률 증가와 의료비 지출 증가 등의 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 진균성 각막염 발병률은 지역에 따라 다르며, 뉴욕의 각막염 환자 중 2%에서 따뜻한 기후의 플로리다에서는 35%에 이릅니다. 또한 토론토에서는 지난 20년간 칸디다가 가장 흔한 균종이었으며, 좋지 않은 임상 결과는 낮은 초기 시력과 이전 각막 이식 병력과 관련이 있었습니다.
게다가 미국에서는 각막염 및 콘택트렌즈 사용과 관련된 외래 진료가 90만 건 이상, 응급실 방문이 5만 8천 건에 달하며, 이는 약 1억 7천 5백만 달러의 의료비 지출로 추산됩니다. 따라서 위의 요인들로 인해 해당 지역의 성장이 촉진될 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 진균성 각막염 치료 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 광범위한 봉쇄와 제한 조치가 시행되면서 전 세계적으로 정기적인 진단, 치료, 신약 출시 및 상담에 차질이 생겼습니다. 팬데믹 발생으로 많은 제약 회사나 의료기기 제조업체는 인력 부족에 직면했고, 봉쇄 조치로 인해 직원들이 출근하지 못했습니다. 따라서 위와 같은 요인들로 인해 향후 예측 기간 동안 진균성 각막염 치료 시장은 다소 영향을 받을 것으로 예상됩니다.
시장 세분화
약물 종류별
• 폴리엔계 항우울제
o 나타마이신
o 암포테리신 B
• 아졸계 항우울제
o 보리코나졸
o 케토코나졸
o 미코나졸
o 플루코나졸
o 이트라코나졸
• 불소화 피리미딘계 항우울제
투여 경로별
• 경구
• 국소
• 정맥주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽 지역
• 남미
o 브라질
o 아르헨티나
o 기타 남미 지역
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양 지역
• 중동 및 아프리카
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Harrow Inc., Thermo Fisher Scientific Inc., Glenmark Pharmaceuticals Limited 등이 있습니다. Cayman Chemical Company, Matinas BioPharma Hldgs, Gilead Sciences Inc., Dr. Reddy’s Laboratories Ltd., Xellia ApS, Merck KGaA, Pfizer Inc. 등이 있습니다.
주요 개발 사항
• 2023년 7월, Harrow는 Santen의 브랜드 안과용 제품 포트폴리오를 인수했습니다. 여기에는 FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE의 미국 및 캐나다 판매권과 비처방 브랜드인 FRESHKOTE 및 Cationorm PLUS가 포함됩니다.
보고서 구매 이유

• 약물, 투여 경로, 유통 채널 및 지역별 글로벌 진균성 각막염 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해
• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 진균성 각막염 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

보고서 구매 이유 • PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.

글로벌 진균성 각막염 시장 보고서는 약 61개의 표, 63개의 그림, 그리고 185페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Fungal Keratitis Treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Fungal keratitis is a fungal infection of the cornea, which can lead to blindness. It generally presents with a red, painful eye and blurred vision. It is an infective process of the cornea caused by any of the multiple pathologic fungi capable of invading the ocular surface.
It is most typically a slow, relentless disease that must be differentiated from other types of corneal conditions with similar presentation, especially its bacterial counterpart, which accounts for the majority of microbial corneal infections. Flavus and A. fumigatus are the most common types of Aspergillus to cause fungal keratitis.
Market Dynamics
The increasing burden of fungal keratitis
The increasing burden of fungal keratitis acts as a significant driver for market growth. Fungal keratitis is an important eye infection, especially in outdoor workers. In most cases, eye trauma, corticosteroid use, or contact lens usage are predisposing factors. Topical drugs are commonly used to treat fungal keratitis and surgery might be required in some rare cases.
For instance, In the United States, warmer regions in the south such as Florida, have a higher frequency of fungal keratitis than cooler regions in the north. In the United States, the most often isolated species causing fungal infections are Fusarium, Candida, and Aspergillus.
Additionally, according to the National Institute of Health Report 2022, male young adults had a higher incidence of fungal keratitis, which can be related to their increased outdoor activity and trauma history. Over 60% of the Chinese patients with fungal keratitis in this major study were male, and over 75% were in the 30- to 60-year-old age range.
Also, according to the American Academy of Ophthalmology, the prevalence varies by region and is highest in South India (36.7% of corneal ulcers) but is also common in West India (36.3%) and East India (26.4%). Fungal keratitis is a much less common cause of corneal ulcers in Northern India (7.3%).
Furthermore, significant growth drivers such as the growing awareness of fungal keratitis, and increasing clinical trials for treatment drugs are expected to drive the market in the forecast period.
Side effects associated with treatment drugs
Treatment drug such as Amphotericin B also interacts with cholesterol in human cell membranes, which is responsible for its toxicity. The most common side effects of amphotericin B include loss of potassium, loss of magnesium, nephrotoxicity, fevers, and anaphylaxis. Hence, the above factors are expected to hamper the market growth.
Segment Analysis
The global fungal keratitis market is segmented based on medication, route of administration, distribution channel and region.
Medication accounted for approximately 56.7% of the market share
Fungal keratitis can be treated with prescription antifungal medicine for several months. Natamycin is currently considered the most effective medication against Fusarium and Aspergillus. Medications are expected to hold the largest market share over the period forecast owing to increasing new clinical trials and various research and developments for treatment drugs.
For instance, according to clinicaltrials.com, on November 5, 2021, the University of California, San Francisco conducted a clinical trial on rose bengal electromagnetic activation with green light for acanthamoeba keratitis and fungal keratitis infection reduction. It is currently in phase 3 and the expected study completion date is July 2025.
Additionally, the Phase 2/Phase 3 study on Combination Treatment of 1% Voriconazole and 5% Natamycin in Fungal Keratitis was finished at the L.V. Prasad Eye Institute in India using a randomized double-masked clinical trial.
Geographical Analysis
North America is expected to hold a significant position in the global fungal keratitis treatment market share
The global fungal keratitis treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of fungal keratitis, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, the incidence of fungal keratitis varies according to geographic location and ranges from 2% of keratitis cases in New York to 35% in warm weather Florida. Also, in Toronto, Candida had been the most common species over a 20-year period and the poor clinical outcome was associated with low presenting visual acuity and previous corneal transplant.
Additionally, there are more than 900,000 physician visits and 58,000 emergency visits related to keratitis and contact lens use in the US, accounting for an estimated expenditure of around $175 million dollar in health care. Thus, owing to the above factors, it is expected to drive the region's growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global fungal keratitis treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the fungal keratitis treatment market is expected to be moderately affected over the forecast period.
Market Segmentation
By Medication
• Polyenes
o Natamycin
o Amphotericin B
• Azoles
o Voriconazole
o Ketoconazole
o Miconazole
o Fluconazole
o Itraconazole
• Fluorinated Pyrimidines
By Route of Administration
• Oral
• Topical
• Intravenous
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Harrow Inc., Thermo Fisher Scientific Inc., Glenmark Pharmaceuticals Limited, Cayman Chemical Company, Matinas BioPharma Hldgs, Gilead Sciences Inc., Dr. Reddy’s Laboratories Ltd., Xellia ApS, Merck KGaA, Pfizer Inc. among others.
Key Developments
• In July 2023, Harrow acquired Santen’s branded ophthalmic portfolio that includes U.S. and Canadian Commercial Rights to FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and Non-Prescription Brands FRESHKOTE and Cationorm PLUS.
Why Purchase the Report?
• To visualize the global fungal keratitis market segmentation based on medication, route of administration, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of fungal keratitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global fungal keratitis market report would provide approximately 61 tables, 63 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Medication
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing burden of fungal keratitis
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with treatment drugs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Medication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
7.1.2. Market Attractiveness Index, By Medication
7.2. Polyenes*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Natamycin
7.2.4. Amphotericin B
7.3. Azoles
7.3.1. Voriconazole
7.3.2. Ketoconazole
7.3.3. Miconazole
7.3.4. Fluconazole
7.3.5. Itraconazole
7.4. Fluorinated Pyrimidines
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Intravenous
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Harrow Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc
12.3. Glenmark Pharmaceuticals Limited
12.4. Cayman Chemical Company
12.5. Matinas BioPharma Hldgs
12.6. Gilead Sciences Inc.
12.7. Dr. Reddy’s Laboratories Ltd.
12.8. Xellia ApS
12.9. Merck KGaA
12.10. Pfizer Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Harrow Inc., 4.	Key Developments, Thermo Fisher Scientific Inc, Glenmark Pharmaceuticals Limited, Cayman Chemical Company, Matinas BioPharma Hldgs, Gilead Sciences Inc., Dr. Reddy’s Laboratories Ltd., Xellia ApS, Merck KGaA, Pfizer Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Fungal Keratitis Market Value, By Medication, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Fungal Keratitis Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Fungal Keratitis Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Fungal Keratitis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Fungal Keratitis Market Value, By Medication, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Fungal Keratitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 7 Global Fungal Keratitis Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Fungal Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Fungal Keratitis Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Fungal Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Fungal Keratitis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Fungal Keratitis Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Fungal Keratitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 14 North America Fungal Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Fungal Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Fungal Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Fungal Keratitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 18 South America Fungal Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Fungal Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Fungal Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Fungal Keratitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 22 Europe Fungal Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Fungal Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Fungal Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Fungal Keratitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Fungal Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Fungal Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Fungal Keratitis Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Fungal Keratitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Fungal Keratitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Fungal Keratitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Harrow Inc.: Overview

Table 33 Harrow Inc.: Product Portfolio

Table 34 Harrow Inc.: Key Developments

Table 35 Thermo Fisher Scientific Inc: Overview

Table 36 Thermo Fisher Scientific Inc: Product Portfolio

Table 37 Thermo Fisher Scientific Inc: Key Developments

Table 38 Glenmark Pharmaceuticals Limited: Overview

Table 39 Glenmark Pharmaceuticals Limited: Product Portfolio

Table 40 Glenmark Pharmaceuticals Limited: Key Developments

Table 41 Cayman Chemical Company: Overview

Table 42 Cayman Chemical Company: Product Portfolio

Table 43 Cayman Chemical Company: Key Developments

Table 44 Matinas BioPharma Hldgs: Overview

Table 45 Matinas BioPharma Hldgs: Product Portfolio

Table 46 Matinas BioPharma Hldgs: Key Developments

Table 47 Gilead Sciences Inc.: Overview

Table 48 Gilead Sciences Inc.: Product Portfolio

Table 49 Gilead Sciences Inc.: Key Developments

Table 50 Dr. Reddy’s Laboratories Ltd.: Overview

Table 51 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 52 Dr. Reddy’s Laboratories Ltd.: Key Developments

Table 53 Xellia ApS: Overview

Table 54 Xellia ApS: Product Portfolio

Table 55 Xellia ApS: Key Developments

Table 56 Merck KGaA: Overview

Table 57 Merck KGaA: Product Portfolio

Table 58 Merck KGaA: Key Developments

Table 59 Pfizer Inc.: Overview

Table 60 Pfizer Inc.: Product Portfolio

Table 61 Pfizer Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 2 Global Fungal Keratitis Market Share, By Medication, 2022 & 2031 (%)

Figure 3 Global Fungal Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Fungal Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Fungal Keratitis Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Fungal Keratitis Market Y-o-Y Growth, By Medication, 2022-2031 (%)

Figure 7 Polyenes Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 8 Azoles Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 9 Fluorinated Pyrimidines Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 10 Global Fungal Keratitis Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 11 Oral Route of Administration in Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 12 Topical Route of Administration in Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 13 Intravenous Route of Administration in Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 14 Global Fungal Keratitis Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 15 Hospital Pharmacy Distribution Channel in Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 16 Retail Pharmacy Distribution Channel in Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 17 Online Pharmacy Distribution Channel in Global Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 18 Global Fungal Keratitis Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 19 North America Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 20 Asia-Pacific Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 21 Europe Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 22 South America Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 23 Middle East and Africa Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 24 North America Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 25 North America Fungal Keratitis Market Share, By Medication, 2022 & 2031 (%)

Figure 26 North America Fungal Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 27 North America Fungal Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 28 North America Fungal Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 29 South America Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 30 South America Fungal Keratitis Market Share, By Medication, 2022 & 2031 (%)

Figure 31 South America Fungal Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 32 South America Fungal Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 33 South America Fungal Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 34 Europe Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Fungal Keratitis Market Share, By Medication, 2022 & 2031 (%)

Figure 36 Europe Fungal Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 37 Europe Fungal Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 38 Europe Fungal Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 39 Asia-Pacific Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 40 Asia-Pacific Fungal Keratitis Market Share, By Medication, 2022 & 2031 (%)

Figure 41 Asia-Pacific Fungal Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 42 Asia-Pacific Fungal Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 43 Asia-Pacific Fungal Keratitis Market Share, By, 2022 & 2031 (%)

Figure 44 Asia-Pacific Fungal Keratitis Market Share, By, 2022 & 2031 (%)

Figure 45 Asia-Pacific Fungal Keratitis Market Share, By, 2022 & 2031 (%)

Figure 46 Asia-Pacific Fungal Keratitis Market Share, By, 2022 & 2031 (%)

Figure 47 Asia-Pacific Fungal Keratitis Market Share, By Country, 2022 & 2031 (%)

Figure 48 Middle East & Africa Fungal Keratitis Market Value, 2022-2031 (US$ Million)

Figure 49 Middle East & Africa Fungal Keratitis Market Share, By Medication, 2022 & 2031 (%)

Figure 50 Middle East & Africa Fungal Keratitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 51 Middle East & Africa Fungal Keratitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 52 Harrow Inc.: Financials

Figure 53 Thermo Fisher Scientific Inc: Financials

Figure 54 Glenmark Pharmaceuticals Limited: Financials

Figure 55 Cayman Chemical Company: Financials

Figure 56 Matinas BioPharma Hldgs: Financials

Figure 57 Gilead Sciences Inc.: Financials

Figure 58 Dr. Reddy’s Laboratories Ltd.: Financials

Figure 59 Xellia ApS: Financials

Figure 60 Merck KGaA: Financials

Figure 61 Pfizer Inc.: Financials

세계 진균성 각막염 시장 – 2023-2030

Global Fungal Keratitis Market - 2023-2030